

**Highlights of This Issue 1677****SMALL MOLECULE THERAPEUTICS****1679 Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine**

Raghavendra Gowda,  
 SubbaRao V. Madhunapantula, Omer F. Kuzu,  
 Arati Sharma, and Gavin P. Robertson  
*See related article, p. 1690*

**1690 Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport**

Omer F. Kuzu, Raghavendra Gowda, Arati Sharma,  
 and Gavin P. Robertson  
*See related article, p. 1679*

**1704 EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis**

Ji Yeon Son, So-Yeon Park, Sol-Ji Kim, Seon Joo Lee,  
 Sang-A. Park, Min-Jin Kim, Seung Won Kim,  
 Dae-Kee Kim, Jeong-Seok Nam, and  
 Yhun Yhong Sheen

**1717 Geranylgeranylacetone Blocks Doxorubicin-Induced Cardiac Toxicity and Reduces Cancer Cell Growth and Invasion through RHO Pathway Inhibition**

Polina Sysa-Shah, Yi Xu, Xin Guo, Scott Pin,  
 Djahida Bedja, Rachel Bartock, Allison Tsao,  
 Angela Hsieh, Michael S. Wolin, An Moens,  
 Venu Raman, Hajime Orita, and  
 Kathleen L. Gabrielson

**1729 Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice**

Xiaofei Xu, Bushra Ayub, Zhaojian Liu,  
 Vanida Ann Serna, Wenan Qiang, Yugang Liu,  
 Eva Hernandez, Sonya Zabludoff, Takeshi Kurita,  
 Beihua Kong, and Jian-Jun Wei

**1740 Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy**

Maren Sack, Lirija Alili, Elif Karaman, Soumen Das,  
 Ankur Gupta, Sudipta Seal, and Peter Brenneisen

**1750 Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer**

Kshipra M. Gharpure, Kevin S. Chu,  
 Charles Bowerman, Takahito Miyake,  
 Sunila Pradeep, Selanere L. Mangala, Hee-Dong Han,  
 Rajesha Rupaimoole, Guillermo N. Armaiz-Pena,  
 Tojan B. Rahhal, Sherry Y. Wu, J. Christopher Luft,  
 Mary E. Napier, Gabriel Lopez-Berestein,  
 Joseph M. DeSimone, and Anil K. Sood

**1758 Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling**

Anamaria Balic, Morten Dræby Sørensen,  
 Sara Maria Trabulo, Bruno Sainz Jr, Michele Cioffi,  
 Catarina R. Vieira, Irene Miranda-Lorenzo,  
 Manuel Hidalgo, Joerg Kleeff, Mert Erkan, and  
 Christopher Heeschen

**LARGE MOLECULE THERAPEUTICS****1772 Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice**

Katrin L. Gutbrodt, Giulio Casi, and Dario Neri

**1777 Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients**

Josef Singer, Judit Fazekas, Wei Wang,  
 Marlene Weichselbaumer, Mirosława Matz,  
 Alexander Mader, Willibald Steinfeldner,  
 Sarah Meitz, Diana Mechtcheriakova, Yuri Sobanov,  
 Michael Willmann, Thomas Stockner,  
 Edzard Spillner, Renate Kunert, and  
 Erika Jensen-Jarolim

**1791 Ectodomain-Specific E-Cadherin Antibody Suppresses Skin SCC Growth and Reduces Tumor Grade: A Multitargeted Therapy Modulating RTKs and the PTEN-p53-MDM2 Axis**

Sabine M. Brouxon, Stephanos Kyrkanides,  
 Veena Raja, Andrew Silberfeld, Xiaofei Teng,  
 Denise Trochesset, Jason Cohen, and Li Ma

# Table of Contents

- 1803** **Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex**  
 Sarah M. Cheal, Hong Xu, Hong-fen Guo, Pat B. Zanzonico, Steven M. Larson, and Nai-Kong Cheung
- 1813** **Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells**  
Xiaoming Xie, Yanan Kong, Hailin Tang, Lu Yang, Jennifer L. Hsu, and Mien-Chie Hung
- 1826** **Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma**  
Ning Jiang, Dongsheng Wang, Zhongliang Hu, Hyung Ju C. Shin, Guoqing Qian, Mohammad Aminur Rahman, Hongzheng Zhang, A.R.M. Ruhul Amin, Sreenivas Nannapaneni, Xiaojing Wang, Zhengjia Chen, Gabriela Garcia, Gavin MacBeath, Dong M. Shin, Fadlo R. Khuri, Jun Ma, Zhuo G. Chen, and Nabil F. Saba
- CANCER BIOLOGY AND SIGNAL TRANSDUCTION**
- 1837** **PIK3R3 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Colorectal Cancer**  
Guihua Wang, Xi Yang, Chuan Li, Xiaonian Cao, Xuelai Luo, and Junbo Hu
- 1848** **Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells**  
Weiguo Zhang, Vivian R. Ruvolo, Chen Gao, Liran Zhou, William Bornmann, Twee Tsao, Wendy D. Schober, Paul Smith, Sylvie Guichard, Marina Konopleva, and Michael Andreeff
- 1860** **Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of Silybin against Human Lung Adenocarcinoma Cells *In Vitro* and *In Vivo***  
Zhenxing Liang, Yang Yang, Haibin Wang, Wei Yi, Xiaolong Yan, Juanjuan Yan, Yue Li, Yingtong Feng, Shiqiang Yu, Jian Yang, Zhenxiao Jin, Weixun Duan, and Wensheng Chen
- 1873** **Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma**  
Jasmin R. Agarwal, Qiuju Wang, Toshihiko Tanno, Zeshaan Rasheed, Akil Merchant, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, Farhad Parhami, and William Matsui
- 1882** **Preferential Estrogen Receptor  $\beta$  Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy**  
Samantha C. Ruddy, Rosanna Lau, Miguel A. Cabrita, Chelsea McGregor, Bruce C. McKay, Leigh C. Murphy, James S. Wright, Tony Durst, and M.A. Christine Pratt
- 1894** **Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition**  
Robert Parker, Roderick Clifton-Bligh, and Mark P. Molloy
- 1907** **BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen**  
Vaibhav Sahai, Krishan Kumar, Lawrence M. Knab, Christina R. Chow, Sania S. Raza, David J. Bentrem, Kazumi Ebine, and Hidayatullah G. Munshi
- 1918** **A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance**  
Junfeng Xia, Peilin Jia, Katherine E. Hutchinson, Kimberly B. Dahlman, Douglas Johnson, Jeffrey Sosman, William Pao, and Zhongming Zhao
- 1929** **Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer**  
Luiz Fernando Zerbini, Manoj K. Bhasin, Jaira F. de Vasconcellos, Juliano D. Pაცეზ, Xuesong Gu, Andrew L. Kung, and Towia A. Libermann
- 1942** **MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 Expression**  
Zichao Zhang, KyoungHyun Kim, Xiao Li, Myriam Moreno, Thad Sharp, Micheal J. Goodheart, Stephen Safe, Adam J. Dupuy, and Brad A. Amendt

# Table of Contents

## COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

**1952** Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer

Sharanjot Saini, Shahana Majid, Varahram Shahryari, Z. Laura Tabatabai, Sumit Arora, Soichiro Yamamura, Yuichiro Tanaka, Rajvir Dahiya, and Guoren Deng

## MODELS AND TECHNOLOGIES

**1964** A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant *In Vitro* Multicomponent Analyses


Muhammad Kashif, Claes Andersson, Magnus Åberg, Peter Nygren, Tobias Sjöblom, Ulf Hammerling, Rolf Larsson, and Mats G. Gustafsson

 AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

Particle replication in nonwetting templates (PRINT) is a novel soft lithography process developed to fabricate nanotherapeutics. PRINT nanoparticles improve plasma exposure and increase tumor accumulation of the encapsulated therapeutic. Metronomic delivery of PLGA-PRINT-docetaxel nanoparticles combined with systemic EZH2 siRNA delivery using chitosan nanoparticles resulted in robust antitumor effects in ovarian cancer mouse models. For details, see the article by Gharpure and colleagues on page 1750.



# Molecular Cancer Therapeutics

**13 (7)**

*Mol Cancer Ther* 2014;13:1677-1976.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/13/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/13/7>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.